Paper · 41165026

Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.

Y ASA and 7 others. Asia Pac J Clin Oncol, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions. Papers, record 41165026. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41165026

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.; PubMed
Journal: Asia Pac J Clin Oncol; PubMed
Year: 2026; PubMed
Publication types: Journal Article, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41165026/; PubMed
DOI: https://doi.org/10.1111/ajco.70038; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13568961/; PubMed
The journal: https://conductscience.org/library/journal-index/101241430; PubMed
Citations, by iCite: 1; iCite
Revised in PubMed: 2026-09-13; PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Y ASA	Al-Yafie Shikaha Ahmed
2	Shyn LW	Lee Wei
3	Xiang PBJ	Pong Ben Jun
4	Dhanusha R	Rajendran
5	Michael TR	Tesfagin Reem
6	Yap WH	Wei Hsum
7	Goh BH	Bey Hing	https://orcid.org/0000-0003-1006-3649
8	Wong RS	Rebecca Shin-Yee

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Hematologic Neoplasms	Major topic
Biomarkers, Tumor	Major topic
Humans
Liquid Biopsy
Circulating Tumor DNA
MicroRNAs

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References137

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	28,252,003	Integrating liquid biopsies into the management of cancer.	Nat Rev Clin Oncol	2017	https://conductscience.org/library/papers/28252003	PubMed
2	25,320,245	Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.	Blood	2014	https://conductscience.org/library/papers/25320245	PubMed
3	30,651,634	Targeting FLT3 mutations in AML: review of current knowledge and evidence.	Leukemia	2019	https://conductscience.org/library/papers/30651634	PubMed
4	28,877,839	Significances of MYD88L265P and CXCR4WHIM Mutations in Waldenstrom Macroglobulinemia.	Zhongguo Yi Xue Ke Xue Yuan Xue Bao	2017	https://conductscience.org/library/papers/28877839	PubMed
5	25,296,094	The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.	Kidney Int	2015	https://conductscience.org/library/papers/25296094	PubMed
6	31,704,541	Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance.	Drug Resist Updat	2019	https://conductscience.org/library/papers/31704541	PubMed
7	32,164,715	Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance.	Mol Cancer	2020	https://conductscience.org/library/papers/32164715	PubMed
8	37,248,544	Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing.	Cancer Cell Int	2023	https://conductscience.org/library/papers/37248544	PubMed
9	22,766,978	Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.	Int J Oncol	2012	https://conductscience.org/library/papers/22766978	PubMed
10	30,828,116	The Paraprotein - an Enduring Biomarker.	Clin Biochem Rev	2019	https://conductscience.org/library/papers/30828116	PubMed

1 to 10 of 137

See all 137 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMID	Title	Journal	Year	In Papers
41,976,395	Integrating Artificial Intelligence, Circulating Tumor DNA, and Real-World Evidence to Optimize Hematologic Clinical Trials: Toward Adaptive and Learning Trial Designs.	Cancers (Basel)	2026	https://conductscience.org/library/papers/41976395

Source PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41165026

GET https://conductscience.org/api/papers/v1/41165026/references?page=2

API reference For AI assistants